Animal studies using the BACHD mouse model of HD have suggested that huntingtin lowering therapies targeting the hypothalamus may have beneficial effects on non-motor features such as metabolic dysfunction and depression [22,23]. This evidence concerns the gene HTT and depressive disorder.